Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 701–800 of 1,000
Glycoprotein asporin as a novel player in tumour microenvironment and cancer progression
Šimková, D., Kharaishvili, G., Slabáková, E., Murray, P. G., & Bouchal, J. (2016) · Biomedical Papers · doi:10.5507/bp.2016.037 · Cited by 26
Hou, C. M., Qu, X. M., Zhang, J., Ding, T., Han, W., Ji, G. C., Zhong, Z. H., Chen, H., & Zhang, F. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.12.003 · Cited by 24
Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts
Liu, Y., Chen, X., Dai, Y., Jia, Y., Kieffer, Y., Xie, L., Zhou, Z., Tyler, L. A., Kim, A. C., Biffi, G., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.06.001 · Cited by 26
FAP-a and GOLPH3 Are Hallmarks of DCIS Progression to Invasive Breast Cancer
Yu, L., Liu, Z., Tian, Y., Zhao, P., & Hua, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01424 · Cited by 23
Strell, C., Tullberg, A. S., Edelmann, R. J., Akslen, L. A., Malmström, P., Fernö, M., Holmberg, E. C., Östman, A., & Karlsson, P. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06136-4 · Cited by 23
Dorst, D. N., Smeets, E., Klein, C., Frielink, C., Geijs, D. J., Trajkovic‐Arsic, M., Cheung, P. F., Stommel, M. W. J., Gotthardt, M., Siveke, J. T., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00453 · Cited by 23
Kraxner, A., Braun, F., Cheng, W., Yang, T.-H. O., Pipaliya, S. V., Cañamero, M., Andersson, E. K., Harring, S. V., Dziadek, S., Bröske, A.-M. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352632 · Cited by 24
Ferraz, F. S., López, J. L., Lacerda, S. M. D. S. N., Procópio, M. S., Figueiredo, A. F. A., Martins, E. M. N., Guimarães, P. P. G., Ladeira, L. O., Kitten, G. T., Dias, F. F., et al. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111017 · Cited by 24
Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer
Herrera, M., Mezheyeuski, A., Villabona, L. E. E., Corvigno, S., Strell, C., Klein, C., Hölzlwimmer, G., Glimelius, B. L. G., Masucci, G. V., Sjöblom, T., et al. (2020) · Cancers · doi:10.3390/cancers12113238 · Cited by 24
Research progress in tumor targeted immunotherapy
Fang, Y., Yu, A., Ye, L., & Zhai, G. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1882992 · Cited by 23
Animal Models and the Tumor Microenvironment: Studies of Tumor–Host Symbiosis
Lindner, D. J. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.004 · Cited by 25
“Only when FAP depletion was combined with immunization did tumors regress.(16) Transplanted bone marrow cells introduced into tumor-bearing mice comprised 25% of the stromal fibroblasts surrounding the tumor.”
BackgroundGao, Y., Zhang, X., Xia, S., Chen, Q., Tong, Q., Yu, S., An, R., Cheng, C., Zou, W., Liang, L., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.004 · Cited by 25
Cancer immune resistance: can theories converge?
Lu, R. O., Turan, T., Samayoa, J. A., & Marincola, F. M. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170060 · Cited by 22
Hahn, A. W., Venkatesh, N., Msaouel, P., & McQuade, J. L. (2023) · Cells · doi:10.3390/cells12212551 · Cited by 23
DNA vaccines as promising immuno-therapeutics against cancer: a new insight
Shariati, A., Khezrpour, A., Shariati, F. S., Afkhami, H., Yarahmadi, A., Alavimanesh, S., Kamrani, S., Modarressi, M. H., & Khani, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1498431 · Cited by 26
Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models
DeCant, B. T., Principe, D. R., Guerra, C. E., di Magliano, M. P., & Grippo, P. J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00464 · Cited by 24
“However, ablation of a subpopulation of stromal cells (FAP+ cells) permitted immune control of tumor growth and uncovered the efficacy of immunotherapeutic antibodies (anti-CTLA-4 or anti-PD-L1), which resulted in acute tumor regression (Kraman et al., 2010; Feig et al., 2013).”
BackgroundYokota, S. J., Facciponte, J. G., Kelleher, R. J., Shultz, L. D., Loyall, J. L., Parsons, R. R., Odunsi, K. O., Frelinger, J. G., Lord, E. M., Gerber, S. A., et al. (2013) · Europe PMC (PubMed Central) · Cited by 25
Shao, H., Cai, L., Moller, M. G., Issac, B., Zhang, L., Owyong, M., Moscowitz, A. E., Vázquez-Padrón, R. I., Radtke, F., & Liu, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13021 · Cited by 22
“Their contribution to primary and secondary malignancies as well as taking part in drug resistance and tumor recurrence [7, 8] makes CAF potential therapeutic targets.”
BackgroundDevelopment of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma
Hintz, H. M., Cowan, A. E., Shapovalova, M., & LeBeau, A. M. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00206 · Cited by 22
CTL Attenuation Regulated by PS1 in Cancer-Associated Fibroblast
Zhang, H., Jiang, R., Zhou, J., Wang, J., Xu, Y., Zhang, H., Gu, Y., Fu, F., Shen, Y., Zhang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00999 · Cited by 22
Zhang, J., Zuo, T., Yang, J., Hu, Z., Wang, Z., Xu, R., Ma, S., Wei, Y., & Shen, Q. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c18545 · Cited by 22
de Porras, V. R., Pardo, J. C., Notario, L., Etxániz, O., & Pous, A. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094712 · Cited by 24
The Interaction Between Long Non-Coding RNAs and Cancer-Associated Fibroblasts in Lung Cancer
Ti, W., Wang, J., & Cheng, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.714125 · Cited by 22
Jambunathan, K., Watson, D. S., Endsley, A. N., Kodukula, K., & Galande, A. K. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.06.015 · Cited by 22
“In addition, both FAP and POP play roles in inflammation and immunomodulation, though they are incompletely understood [4,15].”
BackgroundZhang, J., Valianou, M., Simmons, H. H., Robinson, M. K., Lee, H., Mullins, S., Marasco, W. A., Adams, G. P., Weiner, L. M., & Cheng, J. D. (2012) · The FASEB Journal · doi:10.1096/fj.12-210377 · Cited by 23
“(16) reported that depletion of FAP-expressing cells in tumor significantly increased the immunological control of tumor growth in lung and pancreatic cancer models, suggesting that FAP is an immune-suppressive component of the tumor stroma.”
BackgroundWu, T., Li, X., Zheng, F., Liu, H., & Yu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1560998 · Cited by 23
Yushkov, B., Черешнев, В. А., Korneva, E. A., Yushkova, V., & Sarapultsev, A. (2025) · Cells · doi:10.3390/cells14130981 · Cited by 24
Nanomedicine for targeting cancer-associated fibroblasts in cancer therapy
Chen, Z., Liu, H.-Z., Shang, Z.-J., Luo, G., & Zhang, X. (2025) · Theranostics · doi:10.7150/thno.120283 · Cited by 22
Multidimensional complexity of cancer. Simple solutions are needed
Sverdlov, E. D. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070099 · Cited by 41
“TME forms a barrier that protects the tumor from external influence, which includes cells of the immune system, and thus takes part in the creation of an immunosuppressive phenotype [38, 39].”
BackgroundHorowitz, M. P., Esakov, E. L., Rose, P. G., & Reizes, O. (2020) · Annals of Translational Medicine · doi:10.21037/atm-2019-cm-08 · Cited by 21
Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential
Chamorro, D. F., Somes, L. K., & Hoyos, V. (2023) · Cancers · doi:10.3390/cancers16010124 · Cited by 25
Qiu, X., Geng, F., Zhang, F.-F., Liu, C., Xu, P., Lu, Z.-Z., Zhang, H., Kong, W., & Yu, X. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.07.054 · Cited by 21
“Moreover, FAPa can facilitate the entry of T effector cells into the tumor by overcoming the immunosuppression and barriers of the tumor microenvironment [10,11].”
BackgroundSingle‐cell advances in stromal‐leukocyte interactions in cancer
Wu, S. Z., & Swarbrick, A. (2021) · Immunological Reviews · doi:10.1111/imr.12976 · Cited by 22
Pfeifer, E., Burchell, J., Dazzi, F., Sarker, D., & Beatson, R. (2021) · Cells · doi:10.3390/cells10071653 · Cited by 23
MacNeil, T., Vathiotis, I. A., Shafi, S., Aung, T. N., Zugazagoitia, J., Gruver, A. M., Driscoll, K. E., & Rimm, D. L. (2021) · Cancers · doi:10.3390/cancers13215501 · Cited by 21
Osborne, B., Yao, T., Wang, X. M., Chen, Y., Kotan, L. D., Nadvi, N. A., Herdem, M., McCaughan, G. W., Allen, J. D., Yu, D. M. T., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.03.015 · Cited by 22
“In particular, the unique tissue distribution of FAP has made it a potential target directed at epithelial cancer stroma [11,12].”
BackgroundLigustilide promotes apoptosis of cancer-associated fibroblasts via the TLR4 pathways
Ma, J., Mei, J., Jia, L., Wang, Y., Hu, M., Ma, F., Long, H., Qin, Z., & Tao, N. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110991 · Cited by 21
Strous, M. T. A., Faes, T. K. E., Gubbels, A. L. H. M., van der Linden, R. L. A., Mesker, W. E., Bosscha, K., Bronkhorst, C. M., Janssen-Heijnen, M. L. G., Vogelaar, F. J., & de Bruïne, A. P. (2022) · Clinical and Translational Oncology · doi:10.1007/s12094-021-02746-y · Cited by 20
Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer
Fertal, S. A., Poterala, J. E., Ponik, S. M., & Wisinski, K. B. (2022) · Cancers · doi:10.3390/cancers14051238 · Cited by 21
Bukhari, M., Patel, N., Fontana, R., Santiago‐Medina, M., Jiang, Y., Li, D., Pestonjamasp, K. N., Christiansen, V. J., Jackson, K. W., McKee, P. A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113302 · Cited by 20
Booijink, R. S., Terstappen, L. W. M. M., Dathathri, E., Isebia, K. T., Kraan, J., Martens, J. W. M., & Bansal, R. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13653 · Cited by 20
Impact of fibroblast activation protein on osteosarcoma cell lines in vitro
Ding, L., Ye, L., Jianli, X., & Jiang, W. G. (2014) · Oncology Letters · doi:10.3892/ol.2014.1788 · Cited by 20
“There is a clear discrepancy between FAP function in tumor promotion and suppression (12,28-30).”
BackgroundModulating the tumor immune microenvironment as an ovarian cancer treatment strategy
Scarlett, U. K., & Conejo-Garcia, J. R. (2012) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.12.41 · Cited by 20
Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts
Li, X., Wang, Y., Zhao, Y., Yang, H., Tong, A., Zhao, C., Shi, H., Li, Y., Wang, Z., & Wei, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1547-5 · Cited by 21
The mesenchyme in malignancy: A partner in the initiation, progression and dissemination of cancer
Glaire, M. A., El-Omar, E. M., Wang, T. C., & Worthley, D. L. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.007 · Cited by 23
Luo, M., Shao, B., Yu, J., Liu, T., Liang, X., Lu, L., Ye, T., He, Z., Xiao, H., & Wei, X. (2017) · Cell Research · doi:10.1038/cr.2017.14 · Cited by 20
Fibroblasts in cancer: Defining target structures for therapeutic intervention
Boesch, M., Baty, F., Rumpold, H. F., Sopper, S., Wolf, D. G. F., & Brutsche, M. H. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.06.003 · Cited by 20
Sun, C., Wang, S., Zhang, Y., Yang, F., Zeng, T., Meng, F., Yang, M., Yang, Y., Hua, Y., Fu, Z., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628677 · Cited by 22
“July 2021 | Volume 11 | Article 628677 suppress the recruitment of immune cells, including abolishing CTLA-4 (45), reducing PD-L1 (46), and inducing Tregs in the tumor stroma to create a tumor-promoting microenvironment (47).”
BackgroundImmune function and dysfunction are determined by lymphoid tissue efficacy
Makris, S., de Winde, C. M., Horsnell, H. L., Cantoral-Rebordinos, J. A., Finlay, R. E., & Acton, S. E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049256 · Cited by 21
“(1) Lymph node FRCs produce the chemokines CCL19 andCCL21 to recruit dendritic cells (DCs) and T cells that express CCR7.”
BackgroundInfluentialSong, P., Pan, Q., Sun, Z. J., Zou, L., & Yang, L. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109830 · Cited by 20
The expression of proline-specific enzymes in the human lung
Vliegen, G., Raju, T. K., Adriaensen, D., Lambeir, A., & Meester, I. D. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.36 · Cited by 23
Garemilla, S. S. S., Gampa, S. C., & Garimella, S. V. (2025) · Medical Oncology · doi:10.1007/s12032-025-02754-w · Cited by 21
Wang, Q., Song, C. W., Zhao, C., Wei, X., De-li, L., Wu, Q., Li, J., & Yang, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145006 · Cited by 24
Yin, Z., Zhou, Y., Zhu, X., Goettl, R. A., Wang, C., Weiss, H. L., Evers, B. M., & Wang, Q. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218060 · Cited by 20
Chen, Z., Feng, X., Pathak, J. L., Fu, Z., Chen, X., Zeng, L., Zheng, Y., Qiu, Q., Qiao, L., & Wu, L. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218410 · Cited by 19
The cancer genome: from structure to function
van Kessel, A. G. (2014) · Cellular Oncology · doi:10.1007/s13402-014-0177-5 · Cited by 25
Pancreatic Tumor Microenvironment
Wang, K., & He, H. Z. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_15 · Cited by 21
Li, Y., Liang, Y., Zhang, S., Wang, X., Zhu, Y.-N., Liu, J., Ren, H., Jiang, W., Wang, J., Zhang, Z., et al. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108537 · Cited by 19
Menyhárt, O., Fekete, J. T., & Győrffy, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112750 · Cited by 20
Pan, Q., Zhao, J., Yang, C., Zhou, Y., Lin, J., Tang, Y., Gu, J., Wang, Q. J., Li, Y., He, J., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1752563 · Cited by 19
A distinct repertoire of cancer‐associated fibroblasts is enriched in cribriform prostate cancer
Hesterberg, A. B., Rios, B. L., Wolf, E. M., Tubbs, C. A., Wong, H. Y., Schaffer, K. R., Lotan, T. L., Giannico, G. A., Gordetsky, J., & Hurley, P. J. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.205 · Cited by 21
Nakamura, K., Kiniwa, Y., & Okuyama, R. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03612-8 · Cited by 19
Combination immunotherapy for pancreatic cancer: challenges and future considerations
Gössling, G. C. D. L., Zhen, D. B., Pillarisetty, V. G., & Chiorean, E. G. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2120471 · Cited by 19
Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
Bryce, A. S., Dreyer, S. B., Froeling, F. E. M., & Chang, D. K.-F. (2022) · Cancers · doi:10.3390/cancers14215302 · Cited by 20
Revisiting the role of T cells in tumor regression
Bercovici, N., & Trautmann, A. (2012) · OncoImmunology · doi:10.4161/onci.18800 · Cited by 22
Miao, Z., Zhao, T., Wang, Z.-N., Miao, F., Xu, Y., Mao, X., Gao, J., & Xu, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-1808-1 · Cited by 19
“As a specific marker of tumor-associated fibrosis, FAP is closely correlated with poor prognosis of a variety of solid tumors [10, 11].”
BackgroundCancer-associated fibroblasts: central players in cancer hallmarks and therapeutic resistance
Lu, Y., Wu, Y., Xu, X., Feng, Y., & Wang, N. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02516-1 · Cited by 18
“Preclinical studies showed that genetic ablation of FAP + fibroblasts in mice can unleash immune attack on tumours: in a lung cancer model, deleting FAP + cells led to accumulation of CD8 + T cells and tumour necrosis [120].”
Alshememry, A. K., Alsaleh, N. B., Alkhudair, N. A., Alzhrani, R. M., & Alshamsan, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.933457 · Cited by 22
“For instance, within the stromal cells, cancer-associated fibroblasts (CAFs), which are the major source of ECM, are associated with immunosuppressive properties (Kraman et al., 2010).”
BackgroundSanti, M. D., Zhang, M., Asam, K. R., Yu, G., Dong, P. M., Sheehan, D. H., Aouizerat, B. E., Thomas, C. M., Viet, C. T., & Ye, Y. (2024) · Journal of Pain · doi:10.1016/j.jpain.2024.104615 · Cited by 18
Arina, A., Karrison, T., Galka, E., Schreiber, K., Weichselbaum, R. R., & Schreiber, H. W. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0293 · Cited by 20
Derakhshandeh, R., Sanadhya, S., Han, K. L., Chen, H., Goloubeva, O. G., Webb, T. J., & Younis, R. H. (2018) · Oncotarget · doi:10.18632/oncotarget.24277 · Cited by 21
“Matrix architecture was reported to define migration of T cells into the stroma of human lung tumor [69, 74] [68].”
BackgroundMM-BMSCs induce naïve CD4+ T lymphocytes dysfunction through fibroblast activation protein α
Wu, X., Wang, Y., Xu, J., Luo, T., Deng, J., & Hu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17538 · Cited by 19
“Hence, the tumor growth was controlled by depleting FAP+ cells in an adaptive immunity-dependent manner, thereby concluding that tumor microenvironment stromal cells exert a suppressive effect on anti-tumor immunity [15, 36].”
BackgroundInfluentialKirschstein, E., Harder, O. E., Krull, J. E., Sikorski, M., Khanal, S., Mack, M., Ware, C. F., Evans, E. E., Gough, M. J., Ma, Q., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.004 · Cited by 19
CD44+ cells enhance pro-tumor stroma in the spatial landscape of colorectal cancer leading edge
Tang, F., Zhu, Y., Shen, J., Yuan, B., He, X., Tian, Y., Weng, L., & Sun, L. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02968-9 · Cited by 17
Strategies to Relieve Immunosuppression in Pancreatic Cancer
Schnurr, M. M., Duewell, P., Bauer, C. A., Rothenfußer, S., Lauber, K., Endres, S., & Kobold, S. (2015) · Immunotherapy · doi:10.2217/imt.15.9 · Cited by 23
Early detection of sporadic pancreatic cancer: time for change
Fric, P., Šedo, A., Škrha, J., Bušek, P., Laclav, M., Škrha, P., & Zavoral, M. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000904 · Cited by 17
Xue, C., Gao, Y., Sun, Z., Li, X., Zhang, M., Yang, Y., Han, Q., Bai, C., & Zhao, R. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837781 · Cited by 17
Jin, J., Barnett, J. D., Krishnamachary, B., Mironchik, Y., Luo, C. K., Kobayashi, H., & Bhujwalla, Z. M. (2022) · Cancer Science · doi:10.1111/cas.15601 · Cited by 18
Myc, L. A., Gamian, A., & Myc, A. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0129-y · Cited by 19
“Therefore, FAP-expressing cells indicate that the tumor microenvironment may play an important role in modulating cancer immunotherapy (Kraman et al. 2010).”
Fakhar-e-alam, M., Akram, M. W., Iqbal, S., Alimgeer, K. S., Atif, M. M., Sultana, K., Willander, M., & Wang, Z. (2017) · Scientific Reports · doi:10.1038/srep46603 · Cited by 17
RetractedRemodeling of Tumor Stroma and Response to Therapy
Johansson, A., & Ganß, R. (2012) · Cancers · doi:10.3390/cancers4020340 · Cited by 19
“Eliminating fibroblast activator protein-positive (FAP) fibroblasts from the tumor environment of Lewis lung carcinoma stimulates a tumor-specific immune response [78].”
BackgroundMeng, J., Bao, W., Liu, M., Ma, Z., & Tian, Z. (2023) · Small · doi:10.1002/smll.202304491 · Cited by 16
Chen, M., Xiao, L., Jia, H., Wang, S., Jiang, X., Lei, X., Zhai, Q., & Lang, J. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109946 · Cited by 16
Exploring the molecular mechanisms and therapeutic potential of SMAD4 in colorectal cancer
Shan, H., Tian, G., Zhang, Y., & Qiu, Z. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2392341 · Cited by 16
“54,55 Furthermore, SMAD4 indirectly shapes a tumor-promoting microenvironment through the transcriptional regulation of inflammatory factors and the impact on tumor cell metabolism.”
BackgroundCancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients
Weber, F. D., Reese, K.-L., Pantel, K., & Smit, D. J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03387-7 · Cited by 16
Suzuki, S., Ishii, G., Matsuwaki, R., Neri, S., Hashimoto, H., Yamauchi, C., Aokage, K., Hishida, T., Yoshida, J., Kohno, M., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1851-8 · Cited by 17
Tumor mechanisms of resistance to immune attack
Zahavi, D. J., & Weiner, L. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.009 · Cited by 17
Microenvironmental modulation of the developing tumour: an immune‐stromal dialogue
Jones, J. O., Moody, W. M., & Shields, J. D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12773 · Cited by 18
Self-citationVatter, F. A. P., Lucotti, S., & Zhang, H. (2020) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-020-09473-0 · Cited by 16
Strell, C., Folkvaljon, D., Holmberg, E. C., Schiza, A., Thurfjell, V., Karlsson, P., Bergh, J. C. S., Bremer, T. M., Akslen, L. A., Wärnberg, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4300 · Cited by 17
Kadota, H., Yuge, R., Shimizu, D., Miyamoto, R., Otani, R., Hiyama, Y., Takigawa, H., Hayashi, R., Urabe, Y., Kitadai, Y., et al. (2022) · Cancers · doi:10.3390/cancers14246146 · Cited by 16
“In a mouse model of breast cancer, tumors treated with anti-CAF therapy transitioned from a Th2 to Th1 response with a prominent increase in CD8+ T cells and a prominent decrease in tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells [32].”
BackgroundPhotodynamic effects of zinc oxide nanowires in skin cancer and fibroblast
Fakhar-e-alam, M., Kishwar, S., & Willander, M. (2013) · Lasers in Medical Science · doi:10.1007/s10103-013-1501-4 · Cited by 16
Shao, H., Kong, R., Ferrari, M. L., Radtke, F., Capobianco, A. J., & Liu, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142815 · Cited by 17
“Their contribution to primary and secondary malignancies [5,6] as well as taking part in drug resistance and tumor recurrence [7,8] make CAF potential targets for therapeutic interventions on the tumor microenvironment (TME).”
BackgroundTanemura, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i40.11396 · Cited by 16
Strategies of targeting pathological stroma for enhanced antitumor therapies
Zhu, Y., Yu, F., Tan, Y., Yuan, H., & Hu, F. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104401 · Cited by 16
Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope
Caron, J. M., Ames, J. J., Contois, L. W., Liebes, L., Friesel, R. E., Muggia, F. M., Vary, C., Oxburgh, L. H., & Brooks, P. C. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.015 · Cited by 17
Expression of CAF-Related Proteins Is Associated with Histologic Grade of Breast Phyllodes Tumor
Kim, H. M., Lee, Y. K., & Koo, J. S. (2016) · Disease Markers · doi:10.1155/2016/4218989 · Cited by 16
“In a meta-analysis that analyzed the clinical implication of FAP overexpression in solid tumors of colorectal cancer, pancreatic adenocarcinoma, non-small cell lung cancer, breast cancer, medullary thyroid carcinoma, and oral squamous cell carcinoma, high FAP expression was related to the risk of distant metastasis (O…”
BackgroundInfluentialUnderstanding organotropism in cancer metastasis using microphysiological systems
Ko, J., Song, J., Lee, Y., Choi, N., & Kim, H. N. (2024) · Lab on a Chip · doi:10.1039/d3lc00889d · Cited by 15
Glabman, R. A., Olkowski, C. P., Minor, H. A., Bassel, L., Kedei, N., Choyke, P. L., & Sato, N. (2024) · Cancers · doi:10.3390/cancers16020449 · Cited by 15
“FAP promotes tumor growth by promoting angiogenesis and ECM remodeling [27] and facilitates the progression of tumors by suppressing the anti-cancer immune response [28,29].”
BackgroundThe role of the microenvironment in tumor growth and spreading
Bitsadze, V. O., Викторовна, С. Е., Солопова, А. Г., Khizroeva, J. K., Yakubova, F. E., Orudzhova, Е. А., Degtyareva, N. D., Егорова, Е., Makatsariya, N. А., Samburova, N. V., et al. (2024) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2024.489 · Cited by 15
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.